Regulators view of HVD drugs [Regulatives / Guidelines]

posted by DavidManteigas – Portugal, 2017-05-16 14:41 (2498 d 15:15 ago) – Posting: # 17357
Views: 22,053

Hi Helmut,

For the sake of curiosity, in your opinion should a regulator approve a generic submited as "highly variable" although all the previous trials reported low CV's? Technically, the criteria are well defined and no objection should be raised in principle. However, should a study that reports an high variation, when all the previous information reports otherwise, be considered scientifically sound for the demonstration of bioequivalence? Ideally, regulators would publish in their product-specific guidelines which compounds could be considered "highly variable"...

Regards,
David

Complete thread:

UA Flag
Activity
 Admin contact
22,940 posts in 4,812 threads, 1,640 registered users;
38 visitors (0 registered, 38 guests [including 5 identified bots]).
Forum time: 04:57 CET (Europe/Vienna)

Those people who think they know everything
are a great annoyance to those of us who do.    Isaac Asimov

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5